Fate Therapeutics Inc (FATE) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Fate Therapeutics reported revenue of $6.6M, down 51.2% from $13.6M the year before. Net income was -$136.3M (a -2051.1% net margin), or -$1.15 per diluted share. Operating margin was -2222.4%. Operating activities generated -$106.1M of cash, leaving -$112.0M of free cash flow. At fiscal year end, Fate Therapeutics held $318.9M in total assets against $111.8M in total liabilities, including $46.6M of cash and equivalents.
Open the full interactive Fate Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Fate Therapeutics Key Stats
| Share Price | $2.00 |
|---|---|
| Market Cap | $240.8M |
| Revenue YoY Growth | -51.2% |
| 52-Week Range | $0.96 – $3.11 |
| Shares Outstanding | 120.4 million (basic, 2026 Q2) |
Fate Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $31.4M | $55.8M | $96.3M | $63.5M | $13.6M | $6.6M |
| Operating Income | -$128.1M | -$217.0M | -$308.4M | -$190.5M | -$210.3M | -$147.7M |
| Pre-Tax Income | -$173.4M | -$212.2M | -$281.7M | -$160.9M | -$186.3M | -$136.3M |
| Income Tax | — | $0 | $0 | $0 | $0 | $2,000 |
| Net Income | -$173.4M | -$212.2M | -$281.7M | -$160.9M | -$186.3M | -$136.3M |
| Diluted EPS | -$2.10 | -$2.24 | -$2.91 | -$1.64 | -$1.64 | -$1.15 |
Fate Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $1.7M | $1.4M | $1.3M | $2.1M |
| Net Income | -$32.2M | -$32.4M | -$31.2M | -$30.2M |
| Diluted EPS | -$0.27 | -$0.27 | -$0.26 | -$0.25 |
Fate Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $167.3M | $133.6M | $61.3M | $41.9M | $36.1M | $46.6M |
| Current Assets | $494.3M | $633.4M | $502.1M | $331.5M | $291.9M | $208.7M |
| Total Assets | $622.5M | $921.5M | $705.6M | $506.2M | $440.7M | $318.9M |
| Current Liabilities | $85.6M | $81.3M | $114.1M | $39.1M | $38.5M | $36.1M |
| Total Liabilities | $238.0M | $242.6M | $221.6M | $137.8M | $122.0M | $111.8M |
| Shareholders' Equity | $384.4M | $678.8M | $483.9M | $368.4M | $318.7M | $207.2M |
Fate Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$39.2M | -$162.9M | -$248.2M | -$132.3M | -$122.9M | -$106.1M |
| Cash From Investing | -$161.1M | -$324.0M | $166.8M | $112.7M | $12.2M | $111.2M |
| Cash From Financing | $282.8M | $453.1M | $9.2M | $85,000 | $99.9M | $5.5M |
| Free Cash Flow | -$44.2M | -$213.6M | -$283.8M | -$138.4M | -$123.6M | -$112.0M |
Figures from Fate Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Fate Therapeutics financials page for every line item.
Fate Therapeutics Company Profile
| Ticker | FATE |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | San Diego, California |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001434316 |
Frequently Asked Questions
What was Fate Therapeutics' revenue in fiscal 2025?
Fate Therapeutics (FATE) reported revenue of $6.6M for fiscal 2025.
What is Fate Therapeutics' annual revenue history?
Fate Therapeutics' annual revenue by fiscal year: 2020: $31.4M; 2021: $55.8M; 2022: $96.3M; 2023: $63.5M; 2024: $13.6M; 2025: $6.6M.
What was Fate Therapeutics' net income in fiscal 2025?
Fate Therapeutics reported net income of -$136.3M for fiscal 2025.
What was Fate Therapeutics' earnings per share (EPS) in fiscal 2025?
Fate Therapeutics' diluted EPS was -$1.15 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Fate Therapeutics generate in fiscal 2025?
Fate Therapeutics generated -$112.0M of free cash flow in fiscal 2025.
What was Fate Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Fate Therapeutics reported revenue of $2.1M.
How many shares of Fate Therapeutics are outstanding?
Fate Therapeutics reported a weighted average of 120.4 million basic shares outstanding in 2026 Q2.
What is Fate Therapeutics' market cap?
Based on its latest closing price, Fate Therapeutics (FATE) has a market capitalization of about $240.8M.
When does Fate Therapeutics' fiscal year end?
Fate Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Fate Therapeutics headquartered?
Fate Therapeutics lists its business address in San Diego, California in its SEC filings.
Fate Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →